建发致新(301584)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

301584 建发致新

已收盘 01-12 15:00:00

{"stockData":{"symbol":"301584","market":"SZ","secType":"STK","nameCN":"建发致新","latestPrice":31.02,"timestamp":1768201383000,"preClose":31.02,"halted":0,"volume":5861462,"delay":0,"changeRate":0,"floatShares":50423900,"shares":421000000,"eps":0.7113,"marketStatus":"已收盘","change":0,"latestTime":"01-12 15:00:00","open":30.96,"high":31.1,"low":30.57,"amount":181000000,"amplitude":0.0171,"askPrice":31.03,"askSize":262,"bidPrice":31.02,"bidSize":332,"shortable":0,"etf":0,"ttmEps":0.7113,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768267800000},"marketStatusCode":5,"adr":0,"adjPreClose":31.02,"symbolType":"stock","openAndCloseTimeList":[[1768181400000,1768188600000],[1768194000000,1768201200000]],"highLimit":34.12,"lowLimit":27.92,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":421288509,"isCdr":false,"pbRate":6.29,"roa":"--","peRate":43.610291,"roe":"14.38%","epsLYR":0.64,"committee":0.209091,"marketValue":13068000000,"turnoverRate":0.1162,"status":2,"floatMarketCap":1564000000},"requestUrl":"/m/hq/s/301584","defaultTab":"news","newsList":[{"id":"2602138550","title":"股市必读：建发致新（301584）1月9日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2602138550","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602138550?lang=zh_cn&edition=full","pubTime":"2026-01-12 03:42","pubTimestamp":1768160530,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，建发致新报收于31.02元，上涨1.77%，换手率11.47%，成交量5.79万手，成交额1.78亿元。董秘最新回复投资者： 公司和科塞尔合作哪些业务？","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200001577.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301584","BK0250"],"gpt_icon":0},{"id":"2602326357","title":"建发致新：公司目前经营正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2602326357","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602326357?lang=zh_cn&edition=full","pubTime":"2026-01-09 16:57","pubTimestamp":1767949026,"startTime":"0","endTime":"0","summary":"证券之星消息，建发致新(301584)01月09日在投资者关系平台上答复投资者关心的问题。投资者提问：大a 15连阳都要4100了，前所未有，但公司市值越来越低 请问公司是不是业绩出问题了，不及时公告？建发致新回复：你好，尊敬的投资者，上市公司股价受市场、行业、经营和交易情绪等多种因素影响，公司目前经营正常，不存在未及时披露信息情形，感谢你的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900026863.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301584"],"gpt_icon":0},{"id":"2602997345","title":"建发致新：与科赛尔医疗合作血管介入产品分销","url":"https://stock-news.laohu8.com/highlight/detail?id=2602997345","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602997345?lang=zh_cn&edition=full","pubTime":"2026-01-09 11:36","pubTimestamp":1767929767,"startTime":"0","endTime":"0","summary":"证券之星消息，建发致新(301584)01月09日在投资者关系平台上答复投资者关心的问题。投资者提问：公司和科塞尔合作哪些业务？能给公司带来多大体量？建发致新回复：你好，尊敬的投资者，公司和科赛尔医疗目前的合作主要为血管介入产品的分销业务，预计年度合作分销规模在1亿元左右，该业务2026年实际分销实施情况受渠道拓展等因素影响，存在一定的不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900015198.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301584","BK0250","159891"],"gpt_icon":0},{"id":"2602392273","title":"股市必读：建发致新（301584）1月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2602392273","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602392273?lang=zh_cn&edition=full","pubTime":"2026-01-09 02:51","pubTimestamp":1767898267,"startTime":"0","endTime":"0","summary":"截至2026年1月8日收盘，建发致新报收于30.48元，上涨0.73%，换手率8.03%，成交量4.05万手，成交额1.23亿元。董秘最新回复投资者： 你好，董秘请问：贵公司除了主营业务，有没有布局新的业务增长点？投资者： 公司业绩增长50%以上就要在1月底前预告，请问公司准备何时预告董秘： 你好，尊敬的投资者，公司财务部门目前在汇总公司2025年度财务数据，公司将基于上市规则要求履行业绩预告（如需）相关的披露要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900001550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301584"],"gpt_icon":0},{"id":"2601331753","title":"建发致新：目前在脑机接口领域没有具体业务布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2601331753","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601331753?lang=zh_cn&edition=full","pubTime":"2026-01-08 11:36","pubTimestamp":1767843376,"startTime":"0","endTime":"0","summary":"证券之星消息，建发致新(301584)01月08日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，未来脑机接口改变世界，请问公司在脑机接口领域有什么布局吗？是否会加大这一领域的投资建发致新回复：你好，尊敬的投资者，公司目前在脑机接口领域没有具体的业务布局，未来将基于公司医疗器械流通平台定位和行业上游、下游需求正常评估和发展这一领域医疗器械产品的销售业务和业务机会（如有）。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800015153.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301584","BK0250"],"gpt_icon":0},{"id":"2601810828","title":"股市必读：建发致新(301584)股东户数2.59万户，较上期减少10.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601810828","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601810828?lang=zh_cn&edition=full","pubTime":"2026-01-07 03:33","pubTimestamp":1767727991,"startTime":"0","endTime":"0","summary":"截至2026年1月6日收盘，建发致新报收于30.15元，上涨0.07%，换手率7.77%，成交量3.92万手，成交额1.18亿元。当日关注点来自“交易信息汇总”：1月6日主力资金净流出332.31万元，散户资金净流入1069.05万元。股本股东变化股东户数变动近日建发致新披露，截至2025年12月31日公司股东户数为2.59万户，较12月19日减少2987.0户，减幅为10.35%。户均持股数量由上期的1.46万股增加至1.63万股，户均持股市值为47.58万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700001578.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301584"],"gpt_icon":0},{"id":"2601892772","title":"建发致新：控股股东下属公司聚焦新兴产业投资","url":"https://stock-news.laohu8.com/highlight/detail?id=2601892772","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601892772?lang=zh_cn&edition=full","pubTime":"2026-01-06 20:53","pubTimestamp":1767703987,"startTime":"0","endTime":"0","summary":"证券之星消息，建发致新(301584)01月05日在投资者关系平台上答复投资者关心的问题。投资者提问：公司及控股大股东旗下是否有产业投资基金？是否有投资一些新兴行业？建发致新回复：公司旗下暂未设立产业投资基金。公司控股股东建发集团下属全资子公司厦门建发新兴产业股权投资有限责任公司是专业的权益类资产管理机构，重点关注国家战略性新兴产业创新与成长的投资机会，重点聚焦先进制造、医疗健康、TMT/消费等新经济领域及AI+与相关未来产业领域的创业投资机会。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600040121.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301584","BK0250"],"gpt_icon":0},{"id":"2601785042","title":"建发致新：经营医疗手术机器人产品分销业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2601785042","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601785042?lang=zh_cn&edition=full","pubTime":"2026-01-06 11:36","pubTimestamp":1767670569,"startTime":"0","endTime":"0","summary":"证券之星消息，建发致新(301584)01月05日在投资者关系平台上答复投资者关心的问题。投资者提问：公司所有业务中，是不是有涉及医疗机器人，脑机等业务？建发致新回复：你好，尊敬的投资者，公司目前的经营活动中，有经营医疗手术机器人产品的分销业务，公司目前不涉及脑机接口产品的制造和分销。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600015898.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301584","159891"],"gpt_icon":0},{"id":"2601850272","title":"建发致新：公司未布局商业航天机器人新能源芯片行业","url":"https://stock-news.laohu8.com/highlight/detail?id=2601850272","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601850272?lang=zh_cn&edition=full","pubTime":"2026-01-06 11:33","pubTimestamp":1767670416,"startTime":"0","endTime":"0","summary":"证券之星消息，建发致新(301584)01月05日在投资者关系平台上答复投资者关心的问题。投资者提问：公司及控股股东是否有产业投资基金等其他资金，有投入商业航天 机器人，新能源，芯片等高科技行业？建发致新回复：你好，尊敬的投资者，公司目前没有通过产业投资者基金布局商业航天、机器人、新能源和芯片等科技行业情形。公司目前并不掌握控股股东建发集团通过投资基金布局商业航天、机器人、新能源和芯片行业的具体信息。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600015677.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["399941","160640","159813","000941.SH","301584","BK0250","159875"],"gpt_icon":0},{"id":"2601850131","title":"建发致新：公司目前销售的产品中不涉及脑机接口产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2601850131","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601850131?lang=zh_cn&edition=full","pubTime":"2026-01-06 11:33","pubTimestamp":1767670406,"startTime":"0","endTime":"0","summary":"证券之星消息，建发致新(301584)01月05日在投资者关系平台上答复投资者关心的问题。投资者提问：公司销售的产品中有应用于脑机相关？建发致新回复：你好，尊敬的投资者，公司目前销售的产品中不涉及脑机接口产品。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600015663.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301584"],"gpt_icon":0},{"id":"2601756859","title":"建发致新：流感期间对IVD诊断产品需求增加","url":"https://stock-news.laohu8.com/highlight/detail?id=2601756859","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601756859?lang=zh_cn&edition=full","pubTime":"2026-01-06 09:06","pubTimestamp":1767661581,"startTime":"0","endTime":"0","summary":"证券之星消息，建发致新(301584)01月05日在投资者关系平台上答复投资者关心的问题。投资者提问：每年年底都是流感爆发期，请问公司4季度，业务销量是否有提升？建发致新回复：你好，尊敬的投资者，流感期间对IVD诊断产品的使用需求会增加。关于公司四季度整体经营情况，公司将在完成年度审计后予以披露。感谢你的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600007244.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301584"],"gpt_icon":0},{"id":"2601291940","title":"股市必读：建发致新（301584）12月31日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2601291940","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601291940?lang=zh_cn&edition=full","pubTime":"2026-01-05 02:25","pubTimestamp":1767551112,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，建发致新报收于29.22元，下跌4.01%，换手率9.49%，成交量4.79万手，成交额1.41亿元。董秘最新回复投资者： 公司所处行业，都是存量竞争 请问公司如何从头部企业虎口夺食？","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500000727.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301584","BK0250"],"gpt_icon":0},{"id":"2595012747","title":"建发致新：基于专业经营与数字应用提升行业地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2595012747","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595012747?lang=zh_cn&edition=full","pubTime":"2025-12-31 11:36","pubTimestamp":1767152179,"startTime":"0","endTime":"0","summary":"证券之星消息，建发致新12月31日在投资者关系平台上答复投资者关心的问题。公司主要通过全国销售网络、专业经营能力和数字开发应用能力形成与行业公司的差异化经营能力。简言之，公司将基于医疗器械流通领域的专业经营能力和数字应用，积极做好现有存量市场和增量市场，在行业竞争中以见贤思齐，以稳健的增长提升行业地位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100018098.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301584","BK0250"],"gpt_icon":0},{"id":"2595379763","title":"建发致新：建发致瑞与公司不存在同业竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2595379763","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595379763?lang=zh_cn&edition=full","pubTime":"2025-12-30 11:34","pubTimestamp":1767065659,"startTime":"0","endTime":"0","summary":"建发致新回复：你好，尊敬的投资者，上海建发致为医疗器械有限责任公司主要经营眼科类医疗高值耗材的分销业务，系公司100%全资控股公司，属于上市公司体系内业务，不存在与控股股东之间的同业竞争的问题。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000016121.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301584","BK0250"],"gpt_icon":0},{"id":"2594294843","title":"建发致新（301584）披露召开2026年第一次临时股东会通知，12月26日股价下跌1.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594294843","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594294843?lang=zh_cn&edition=full","pubTime":"2025-12-26 22:22","pubTimestamp":1766758979,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，建发致新报收于31.13元，较前一交易日下跌1.39%，最新总市值为131.15亿元。该股当日开盘31.66元，最高31.74元，最低31.1元，成交额达1.58亿元，换手率为10.0%。公司近日发布公告，宣布将于2026年1月13日召开2026年第一次临时股东会，会议由董事会召集，现场会议地点为上海市杨浦区秦皇岛路32号上海建发国际大厦9楼1号会议室。股权登记日为2026年1月8日，股东可通过现场或网络投票方式参与。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600036397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301584"],"gpt_icon":0},{"id":"2594916752","title":"建发致新：无逾期担保的情形","url":"https://stock-news.laohu8.com/highlight/detail?id=2594916752","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594916752?lang=zh_cn&edition=full","pubTime":"2025-12-26 21:33","pubTimestamp":1766755980,"startTime":"0","endTime":"0","summary":"证券日报网讯 12月26日，建发致新发布公告称，公司及控股子公司未对合并报表外单位提供担保。公司无逾期担保的情形，不存在涉及诉讼的担保及因担保被判决败诉而应承担损失等情形。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-26/doc-inhecwez7848629.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-26/doc-inhecwez7848629.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0250","301584"],"gpt_icon":0},{"id":"2594263071","title":"建发致新：目前医疗器械SPD管理业务主要竞争对手有国药集团、上海医药、华润医药等","url":"https://stock-news.laohu8.com/highlight/detail?id=2594263071","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594263071?lang=zh_cn&edition=full","pubTime":"2025-12-26 11:36","pubTimestamp":1766720166,"startTime":"0","endTime":"0","summary":"证券之星消息，建发致新(301584)12月25日在投资者关系平台上答复投资者关心的问题。投资者提问：公司spd 系统，目前竞争对手有哪几家，份额占比多少建发致新回复：你好，尊敬的投资者。目前医疗器械SPD管理业务行业主要竞争对手有国药集团、上海医药、华润医药等医药商业企业，除此之外存在部分SPD专业管理公司如国医科技、德荣医疗、塞力医疗等。市场份额方面，根据部分市场报告显示，国药集团目前居于行业主导地位，其余公司呈现分散竞争的格局。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600012621.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0196","09996","03320","BK1100","601607","BK1570","301584","BK0097","159883","BK0020","02607","BK0184","BK0183","BK1583","BK0209","BK0187","BK0012","BK0099","BK1574","BK0028","BK1191","BK0250","BK1197","BK0175","BK1222","09997"],"gpt_icon":0},{"id":"2594505802","title":"建发致新：截止12月19日股东数量为28,857名","url":"https://stock-news.laohu8.com/highlight/detail?id=2594505802","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594505802?lang=zh_cn&edition=full","pubTime":"2025-12-26 09:24","pubTimestamp":1766712252,"startTime":"0","endTime":"0","summary":"证券之星消息，建发致新(301584)12月25日在投资者关系平台上答复投资者关心的问题。投资者提问：截止12.23号，公司股东多少户？建发致新回复：你好，尊敬的投资者，截止最近一次查询日12月19日，公司股东数量为28,857名。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600005292.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301584"],"gpt_icon":0},{"id":"2594925397","title":"股市必读：建发致新（301584）12月25日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2594925397","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594925397?lang=zh_cn&edition=full","pubTime":"2025-12-26 01:46","pubTimestamp":1766684777,"startTime":"0","endTime":"0","summary":"截至2025年12月25日收盘，建发致新报收于31.57元，下跌0.79%，换手率9.19%，成交量4.63万手，成交额1.46亿元。公司公告汇总关于公司高级管理人员辞职的公告上海建发致新医疗科技集团股份有限公司董事会近日收到高级管理人员程芳女士提交的书面辞职报告。程芳女士因个人原因辞去公司副总经理职务，辞职后不再担任公司高级管理职务，但仍继续在公司工作。其辞职报告自送达董事会之日起生效，不会影响公司正常经营。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600000562.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301584"],"gpt_icon":0},{"id":"2594237674","title":"建发致新（301584）披露公司高级管理人员辞职公告，12月25日股价下跌0.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594237674","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594237674?lang=zh_cn&edition=full","pubTime":"2025-12-25 22:21","pubTimestamp":1766672486,"startTime":"0","endTime":"0","summary":"截至2025年12月25日收盘，建发致新报收于31.57元，较前一交易日下跌0.79%，最新总市值为133亿元。公司近日发布公告称，上海建发致新医疗科技集团股份有限公司董事会近日收到高级管理人员程芳女士提交的书面辞职报告。程芳女士因个人原因辞去公司副总经理职务，辞职后不再担任公司高级管理职务，但仍继续在公司工作。其辞职报告自送达董事会之日起生效，不会影响公司正常经营。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500036051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301584","BK0250"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768203146744,"stockEarnings":[{"period":"1week","weight":0.0616},{"period":"1month","weight":-0.1019},{"period":"3month","weight":0.148},{"period":"6month","weight":3.4},{"period":"ytd","weight":0.0616}],"compareEarnings":[{"period":"1week","weight":0.0382},{"period":"1month","weight":0.0564},{"period":"3month","weight":0.0573},{"period":"6month","weight":0.1739},{"period":"1year","weight":0.2831},{"period":"ytd","weight":0.0382}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海建发致新医疗科技集团股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"25870人(较上一季度减少10.35%)","perCapita":"1949股","listingDate":"2025-09-25","address":"上海市杨浦区杨树浦路288号9层","registeredCapital":"42128万元","survey":"　　上海建发致新医疗科技集团股份有限公司主要从事医疗器械直销及分销业务，并为终端医院提供医用耗材集约化运营（SPD）服务。公司直销和分销业务的产品主要为血管介入器械,外科器械,IVD和医疗设备。公司于2021年被中国物流与采购联合会医疗器械供应链分会评选为“T/CFLP 0023-2019《医药产品医院院内物流服务规范》团体标准试点单位”。","listedPrice":7.05},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"建发致新(301584)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供建发致新(301584)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"建发致新,301584,建发致新股票,建发致新股票老虎,建发致新股票老虎国际,建发致新行情,建发致新股票行情,建发致新股价,建发致新股市,建发致新股票价格,建发致新股票交易,建发致新股票购买,建发致新股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"建发致新(301584)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供建发致新(301584)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}